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Abstract
Objectives: Cinnarizine is used for the treatment of
vestibular disorders. However, its poor solubility limits its
clinical uses due to many challenges. Liposomes were
utilised to improve the release profile of many poorly
soluble drugs. However, liposomes face many stability
challenges during the storage period. This study aims
to develop proliposomes designed for the oral delivery of
cinnarizine with enhanced stability characteristics.
Methods: Three cinnarizine entrapping Proliposomal
formulations were prepared with different ingredients and
compared with their liposomal counterparts. Both vesicu-
lar approaches were characterised for their particle size,
encapsulation efficiency, drug release and stability.
Results: The proliposomes were superior to liposomes
in their stability and release profiles. Although no sig-
nificant changes were noticed between the encapsulation
efficiency percentage of the liposomal and proliposomal
formulations on the day of preparation, storing the for-
mulations for two weeks ended up with significant
leakage of the drug from liposomes (p < 0.05) due to
stability issues, but not in proliposomes. Moreover, the
proliposomes released 100% of cinnarizine throughout
the dissolution experiment in gastric fluid in comparison
with the total released drug of 70% from the liposomes.
Conclusions: Proliposomes provided a successful approach
to deliver lipophilic drugs orally to improve their
pharmacokinetic properties by converting their crystal-
line nature into more amorphous agents.
Keywords: liposomes; proliposomes; lipid delivery
systems; cinnarizine; oral delivery.
Introduction
Cinnarizine is a first-generation antihistamine. One of the
main side effects of cinnarizine is the induced drowsiness
which became the main therapeutic indications due to its
central effect in managing vestibular disorders, e.g. ver-
tigo, Meniere’s disease, and tinnitus [1, 2]. Cinnarizine
is a class II drug according to the biopharmaceutical
classification system (BCS); it has very good permeation
and poor solubility, which may limit its oral uses [3].
Despite the long half-life cinnarizine has, the frequency of
administration is three to four times a day as a result of its
limited solubility as the GI fluid is not able to dissolve such
a high amount of the drug all at once. Cinnarizine is well
absorbed in the upper gastrointestinal tract (GIT) due to its
high lipophilic properties; however, the same properties
limit the solubility and the readiness for absorption as a
limiting step [4]. Therefore, enhancing the drug solubility
and dissolution profile may be the key to improving
the pharmacokinetic properties of the therapeutic agent.
Many techniques are utilised to overcome the solubility
limitations of cinnarizine, e.g. niosome [5] and complex-
ation and conjugation [6]. Nanotechnology-based drug
delivery systems opened newhorizons for the oral delivery
of many small drugs and macromolecules [7, 8]. Lipo-
somes [9], polymeric nanoparticles [10], niosomes [11],
and nanoemulsions [12] are considered the most common
examples of nanocarriers that are utilised for oral delivery.
Liposomes are bilayer phospholipid spherical vesicles
with aqueous and lipophilic domains. The amphipathic na-
tureof liposomesmakes themgreatpotential delivery systems
for a wide variety of active pharmaceutical ingredients.
Liposomes have multipurpose structure and intrinsic prop-
erties that provided them with advanced applications. The
popularity of liposomes is owed to their meritorious features;
biocompatibility, biodegradability, non-immunogenicity,
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and safety [13]. Many studies revealed the prominent roles
that liposomes play in the field of drug delivery systems. Li-
posomes have great potential in enhancing drug solubility,
providing targeted delivery systems, modifying and extend-
ing drug release, and improving the safety profile and phar-
macokinetic properties of delivered drugs [14, 15]. However,
physical, chemical and biological stability issues burden the
successful development of liposomes due to many processes
that happen during the storage and delivery of liposomes
which may induce phospholipid hydrolysis and oxidation
and vesicles aggregation, sedimentation and fusion [5, 16].
Therefore, the approaches for stabilising phospholipid vesi-
cles are emerging and necessary to enhance the clinical and
preclinical applications of liposomes; e.g. Polyethylene glycol
functionalisation [17] and using synthetic phospholipids with
boosted stabilising properties [18].
Proliposomes are a promising approach to improve
physicochemical properties, release profile and pharmaco-
kinetic characteristics, and the stability of liposomes [19,
20]. Proliposomes are dry flowable particles that produce a
suspension of liposomes when reconstituted with aqueous
solvents [21]. Proliposomes have been advocated to over-
come the limitations of the oral delivery of lipophilic drugs
by promoting their absorption, owing to their interaction
with bile salts in the GIT to formmixed micellular system of
vehicles/mesophases and convert the intrinsic nature of
some drugs from being crystalline into agents with more
amorphous properties [22–25].
In this study, we prepared proliposomal and liposomal
formulations containing different lipid: cholesterol ratios
with and without cremophor by using the thin lipid film
hydration method. All formulations were characterised for
their physicochemical properties and release profile. This
study aimed to develop and characterise proliposomal
formulations designed for the oral delivery of cinnarizine.
A critical comparison between the proliposomal formula-
tions and their liposomal counterparts were held.
Materials and methods
Materials
Lipid 1,2-Distearoyl-sn-glycerol-3-phosphocholine (DSPC), choles-
terol, cinnarizine was purchased from all known company Sigma-
Aldrich. The cosurfactant cremophor® EL (polyethoxylated castor
oil) was purchased from BASF Aktiengesellschaft (Ludwigshafen,
Germany). The solvents; chloroform, dichloromethane, and hydro-
chloric acid were from Fischer Chemicals and freshly prepared
distilled water was used for the further dilutions of 0.1 N HCl.
Methods
Liposomes and proliposomes were formulated with different lipid:
cholesterol ratios with or without cremophor by using the thin lipid
film hydration method. Liposomes were prepared as described earlier
by [14]. Briefly, individual solutions of lipid, cremophor, cholesterol,
or cinnarizine in chloroform were prepared and transferred into a
round-bottom flask. Then, the organic solvent was evaporated by a
rotary evaporator (Rotavapor R205, Buchi Labortechnik AG,
Switzerland) at 60 °C, 100 rpm, and 464 ± 10mbar pressure until a thin
filmwas produced. The obtained film was hydrated with 0.1 N HCl in a
shaking water bath at 60 °C for 1 h and left to cool down. Afterwards,
the systems were bath sonicated for 10 min to reduce and uniform the
particle size by producing unilamellar vesicles. The free drug was
separated from the vesicles by passing the suspension through size
exclusion Sephadex™ G-25 Medium columns (Prepacked PD-10
Desalting, GE); all illusion fractions were collected. The last frac-
tions that contain liposomes were characterised and kept for later
stability tests. For the proliposomal formulations, the suspensions
were centrifugated and washed in distilled water twice at 15,000 rpm,
4 °C, for 30min. The supernatantswere discarded, and the pelletswere
collected and kept in Eppendorf inside a bucket of ice and dried under
the fume cupboard for 24 h. Afterwards, the obtained powders
were sieved through #120 mesh to improve the flowability of the
proliposomal formulations andbreak downany aggregates to produce
uniform particles.
Then, the prepared formulations were characterised for their
physicochemical properties, drug release and 14 days storage stability.
The proliposomes were resuspended on the day of characterisation by
adding 5 ml prewarmed saline and hand-shaking the samples until they
are entirely homogeneous. Particle size analysis for all formulations was
investigated by using Zeta PALS (Brookhaven Instruments Corporation,
USA), particle size in nm and PDI results are the average of triplicate
readings. Size analysis for all formulations was performed on the day of
preparation by further diluting the samples and vertexing them for uni-
formity. Moreover, the encapsulation efficiency of all formulations was
investigated on the same day of preparation and after 14 days of storage
at chilled conditions (5 °C ± 2). The rationale of measuring the encap-
sulation efficiency after storing the formulations was to examine the
leakage of the drug from the vesicles in liposomes and proliposomes.
Diluted 1 ml of suspension in 0.1 N HCl was diluted with 2 ml of
chloroform to dissolve liposome ingredients. Once the systems turned
into a clear solution, the absorbancewasmeasured at λ = 253 nmusing
a single-beamUV/Vis Spectrophotometer (CamspecM501, UK) against
1:2 HCl: chloroform as a blank reference. The release profile of both
vesicles was investigated in simulated gastric fluid (SGF) to assess
their potential to release the drug in the stomach. The dissolution
studywas carried out in Eppendorf vials (1.25ml) for a total time of 4 h.
One vial for each time point of every samplewas allocated in a shaking
water bath at 37 ± 0.5 °C with 100 rpm. At the end of each time point,
the vials were collected, washed twice by centrifugation at
10,000 rpm, and the absorbance at λ = 253 nm (A253) was measured.
The concentration was calculated by substituting the obtained
absorbance in the generated equation by plotting a series of concen-
trations (2–20 μg/ml drug in 0.1 N HCl) vs A253 by utilising a single
beam UV/Vis Spectrophotometer, Eq. (1).
y = 0.594x + 0.0269 R2 = 0.9988 (1)
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All results are presented as the mean of triplicate ± standard
deviation (SD). Paired sample T-tests were performed, and the two-
tailed significance (p-value) was determined, and p-value ≤ 0.05 was
considered statistical significance.
Results and discussion
DSPC phospholipid was selected in this study due it its
proven superiority in physicochemical properties over
other phospholipids; namely, DMPC and DPPC. The
rigidity of DSPC makes it a great potential for formulating
stable liposomes for in vivo administration and for with-
standing throughout storage [23]. Cholesterol was used at
different amounts for its role in reducing the fluidity of the
liposomal shell and increasing their packing density and
mechanical properties [26]. Liposomes and proliposomes
were prepared with different lipid: cholesterol ratios.
Liposomes were kept and stored as suspensions in
Phosphate buffer saline as the acidic media may enhance
the leakages of cinnarizine to the outer shell due to its
good solubility at low pH values and poor solubility at pH
values above 6 [27]. The Proliposomal formulations were
dried and formed dry and fluffywhitish powder and turbid
milky suspension upon reconstitution. The particle
size analysis revealed that all formulations were in the
nanoscale with no significant effect of changing the in-
gredients, and their amount was reported. However, the
particle size of the proliposomes was significantly larger
than their counterpart liposomes, Table1. The large par-
ticle size of proliposomes is attributed to the formation of
multilamellar vesicles upon reconstitution with water as
reported by [23]. The multilamellar vesicles have larger
intra-layer spaces that can be considered as a lipophilic
domain suitable for entrapping poorly soluble drugs.
According to the FDA, PDI is an essential component and
critical quality attribute that should usually be considered
in evaluating liposomal drug products. The recorded PDI
ranges from 0.1–0.3 for all formulations without extreme
readings. In liposomal formulations, PDI readings less
than 0.3 are acceptable and represent homogenous
colloidal systems. In contrast, polymer-based nano-
carriers should have PDI values less than 0.2 to be
considered acceptable [28]. PDI readings were changed
after the period of storage; however, all of them remained
within the same range (0.1–0.3).
This feature may increase the amount of the encap-
sulated cinnarizine in proliposomes upon contact with
water and body fluids. The encapsulation efficiency values
were similar for all formulation when measured on the
same day of formulations. The formulations that do not
contain cremophor (L3 and PL3) showed slightly higher
entrapment efficiency; however, the difference was not
significant, P > 0.05. Cremophore is a cosurfactant thatmay
increase the solubility of the drug in the surroundingmedia
and facilitate their leakage outside the vesicles. All for-
mulations were stored in the fridge at 5 °C ± 2 °C for 14 days
to address any changes in the amount of confined drugs
over the period of storage. Although the liposomes were
kept in PBS, which is considered a weak solvent for cin-
narizine; surprisingly, the EE% was significantly reduced
with storage. The leakagemay have happened due tomany
factors. On top of these factors is the addition of cremophor
as a cosurfactant and the stability issues that phospholipid
may face during the storage [29]. In this study, one lipo-
somal formulation was prepared without using cremophor
at any concentration (L3). Thus, if the leakage was caused
due to the increase in the solubility of cinnarizine in the
surrounding, the encapsulation efficiency of L3 should not
have been affected over the time of storage. However, the
Table : Optimisation of the liposomal and proliposomal formulations encapsulating cinnarizine (model hydrophobic small drug) and their
physicochemical properties.
ID Cinnarizine, mg Lipid: Cholesterol:
Cremophor ratio
Size (nm)a,b PDIa %EEc,b %Drug released,b
L  :: . ± . . . ± . . ± .
L  :: . ± . . . ± . . ± .
L  :: . ± . . . ± . . ± .
PL  :: . ± . . . ± . . ± .
PL  :: . ± . . . ± . . ± .
PL  :: . ± . . . ± . . ± .
aSize and PDI were measured by dynamic light scattering in deionised water.bResults are expressed as mean ± SD (n = ).c% Encapsulation
efficiency (%EE) of cinnarizine was determined by measuring absorbance at λ =  nm by single-beam UV/V is spectrophotometer (Camspec
M, UK) against HCl as blank. %EE was determined using the following equation: %EE= (amount of encapsulated drug/initially used drug)
* %.d% of total cinnarizine released in SGF after  he% of EE after  days of storage in the fridge at  ±  °C. Proliposomes were stored in a
desiccator with silica beads.
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percentage of encapsulation efficiency in L3 was depleted
significantly during the 14 days of storage, Figure 1. Also,
changing lipid: cholesterol ratio between L1 and L2 did not
change the case; it means increasing the amount of
cholesterol for the sake of increasing the packing density of
liposomes did not protect the liposomes from degradation
and, consequently, from leakage. These results confirm
that the phospholipid was prone to destabilising events
during the time of storage in the fridge. These stabilising
events may involve physical and chemical processes or
either one.
Proliposomes, the solid powder, kept the same amount
of the entrapped drug over the period of storage. These
unchanged values are expected as the solid systems usu-
ally have zero energy, then no release kinetics may occur;
thus, keeping the same amount of drug inside the vesicles.
Also, the multilamellar nature of proliposomes provided
wide space inside the double layers for confining lipophilic
drugs and more distance for leakage; hence, low leakage
happened.
Drug release was investigated in SGF, Figure 2. Two
different patterns were noticed between the liposomal and
proliposomal formulations. Cinnarizine was released from
the liposomal vesicles, relatively, very quickly. After
90min, around 70%of the drugwas released, and the level
of the released drug remained around the same level.
Reaching a plateau confirms that the drug was diffused
from the area between the bilayer in a saturable manner.
To clarify, after the dissolution of 70% of the drug, the
surrounding dissolution medium reached saturation
without the ability to dissolve any further amount of drug
beyond this. Nevertheless, in proliposomes, the pattern
was completely different; the drug release reached 100%
after 2–4. The sustained-release manner was recorded; the
relationship between the time and the percentage of the
released drug was linear. In multilamellar phospholipid
vesicles, the hydrophobic drugs are confined into the inter-
layer spaces; therefore, at the beginning of the release
process, the drug that exists inside the outer space areawas
diffused and followed gradually by the drug from the other
inter areas. Also, the large particle size of the proliposomes
means a less total surface area the system has; thus,
slower drug release may occur. When a drug is dissolved
gradually, but not suddenly, it has a higher chance to be
dissolved due to the sink condition and the continuous
renewal of the dissolution media. Also, many studies
unveiled the mechanism of increasing the solubility of the
entrapped lipophilic drugs inside proliposomes. Hiremath
et al. concluded that proliposomes have the ability to
convert the physical nature of the loaded hydrophobic
drug from a crystalline into a more amorphous agent,
which consequently enhances the dissolution profile [23].
Figure 1: The percentage of the encapsulation efficiency of
cinnarizine in the liposomal and proliposomal formulations. The
encapsulation efficiency was evaluated on the same day of the
preparation and after 14 days of storage in the fridge. The
quantification was performed by measuring A253 by UV/vis single
beam spectrometer. The amount of confined drug was reduced
significantly over the period of storage *P<0.005. EE% t14 was
significantly different between both types of vesicles, **P<0.01. No
significant difference was reported between EE% t0 for both
liposomes and proliposomes.
Figure 2: In vitro release profile of cinnarizine from the liposomes
and proliposomes in simulated gastrointestinal fluids (without
enzyme) at 37 °C. Cinnarizine release from the formulations was
determined in simulated gastric fluids (SGF) for 4. The SGF was
prepared according to the British Pharmacopeia; however, no
digestive enzymes were added. Drug release was determined by
quantification of cinnarizine amount in SGF by reading A253 after
centrifugation of dissolution vesicles and collecting the
supernatant. The release profile of the drug from the liposomal
formulations was saturable; it reached around 70% after 2 h and
remained the same for the rest of the experiment. However, the
proliposomes released the drug in a sustained pattern throughout
the entire time of the experiment; this confirms the entrapment of
the drug in the hydrophobic domain between the layers of
multilamellar vesicles of proliposomes.
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Conclusion
This study shows a successful case of enhancing the
bioavailability of cinnarizine by utilising proliposomes as
an oral drug carrier. Cinnarizine belongs to class II, where
drugs have good permeation and poor solubility as a main
barrier for bioavailability. Liposomes could benefit the
clinical uses of cinnarizine by enhancing its dissolution
profile and its pharmacokinetic properties. However,
liposomes are facing many stability challenges, which
may burden their storage. Therefore, proliposomes are
pioneered to be dry stored and reconstituted upon usage.
Here, we formulated three different proliposomes and
three liposomes for the oral delivery of cinnarizine with the
same ingredients. Various physicochemical characteris-
tics, drug release, and storage stability were investigated.
Although both approaches utilised the same method of
preparation which ended up with the same encapsulation
efficiency, significant differences were reported in term of
drug release and stability over 14 days of storage. Proli-
posomes have shown superiority to their liposomal coun-
terparts in term of stability and drug release. Proliposomes
showed slower and extended-release in comparison to the
liposomal formulations. In proliposomes, the entire
encapsulated drug was released over the time of the
experiment (4 h). In conclusion, proliposomes may play a
crucial role, as an oral delivery system, in comparison with
liposomes, which is owed to their ability to achieve full and
sustained drug release in SGF andwithstand over the entire
period of storage with full protection of loaded drugs.
Hence, proliposomal formulations have established their
position in oral drug delivery systems, and this study
may open new horizons for many researchers to further
investigate this field to improve the bioavailability of many
poorly soluble drugs. In order to enhance the feasibility
and applicability of the developed proliposomes, further
drying techniques and conditions should be investigated,
e.g. lyophilisation or spray drying. Noteworthy, scanning
and investigating a range of cryoprotectant is recom-
mended to obtain the most stable formulations.
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